Five Prime Therapeutics licenses new target to UCB from its protein discovery platform
Five Prime Therapeutics announced UCB has elected to exclusively license an undisclosed drug target for inflammatory diseases. Five Prime identified the target using its discovery platform, and is eligible to receive potential future development, regulatory and sales-based milestones payments. March 19, 2018